Nontuberculous mycobacteria infection Market Insights, Epidemiology and Market Forecast  2028

Nontuberculous mycobacteria infection Market Insights, Epidemiology and Market Forecast 2028

  • Pages: 120
  • Geography: 7MM (US, EU5, & Japan)
  • Delivery Timeline: 7-10 Business Days
  • Publication: Jul, 2019
  • SKU: DIMI0602
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

Nontuberculous Mycobacteria infection Market | Nontuberculous Mycobacteria infection  Market Research Report

DelveInsight's “Nontuberculous Mycobacteria infection - Market Insights, Epidemiology and Market Forecast – 2028” report provides  the detailed overview of the disease and in depth understanding of historical and forecasted Nontuberculous Mycobacteria infection  epidemiology. It highlights the existing treatment patterns, potential upcoming Nontuberculous Mycobacteria infection  drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Nontuberculous Mycobacteria infection Understanding and Treatment Algorithm

The Nontuberculous Mycobacteria infection market report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Nontuberculous Mycobacteria infection in the US, Europe, and Japan are also provided in the report.

Nontuberculous Mycobacteria infection Epidemiology

This section provide the insights about historical and current Nontuberculous Mycobacteria infection  patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Nontuberculous Mycobacteria infection Product Profiles & Analysis

This part of the report encloses the detailed analysis of Nontuberculous Mycobacteria infection  marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals,  patent details and other major breakthroughs.

Nontuberculous Mycobacteria infection Market Outlook

The Nontuberculous Mycobacteria infection market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders[S1] . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight. Nontuberculous Mycobacteria infection Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Nontuberculous Mycobacteria infection Report Insights

  • Nontuberculous Mycobacteria infection Patient Population
  • Nontuberculous Mycobacteria infection Therapeutic Approaches
  • Nontuberculous Mycobacteria infection Pipeline Analysis
  • Nontuberculous Mycobacteria infection Market Size and Trends
  • Nontuberculous Mycobacteria infection Market Opportunities
  • Impact of upcoming Therapies in Nontuberculous Mycobacteria infection

Nontuberculous Mycobacteria infection Report Key Strengths

  • Nontuberculous Mycobacteria infection 10 Year Forecast
  • Nontuberculous Mycobacteria infection  7MM Coverage
  • Nontuberculous Mycobacteria infection  Epidemiology Segmentation
  • Nontuberculous Mycobacteria infection Drugs Uptake
  • Highly Analyzed Nontuberculous Mycobacteria infection  Market
  • Key Cross Competition

Nontuberculous Mycobacteria infection Report Assessment

  • Current Treatment Practices in Nontuberculous Mycobacteria infection
  • Nontuberculous Mycobacteria infection  Unmet Needs
  • Detailed Nontuberculous Mycobacteria infection Pipeline Product Profiles
  • Nontuberculous Mycobacteria infection Market Attractiveness
  • Nontuberculous Mycobacteria infection Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Nontuberculous Mycobacteria infection market
  • Organize sales and marketing efforts by identifying the best opportunities for Nontuberculous Mycobacteria infection market
  • To understand the future market competition in the Nontuberculous Mycobacteria infection market.
1>1.     Report Introduction 1>2.     Nontuberculous Mycobacteria infectioninfectionMarket Overview at a Glance 1>2.1. Market Share Distribution of Nontuberculous Mycobacteria infectioninfectionin 2017 1>2.2. Market Share Distribution of Nontuberculous Mycobacteria infectioninfectionin 2028 1>3.     Disease Background and Overview: Nontuberculous mycobacteria 1>3.1. Introduction 1>3.2. Symptoms 1>3.3. Etiology 1>3.4. Risk Factors 1>3.5. Pathophysiology 1>3.6. Diagnosis 1>3.7. Treatment 1>4.     Epidemiology and Patient Population 1>4.1. Key Findings 1>4.2. Total Prevalent/ Incident Patient Population of Nontuberculous Mycobacteria infectioninfectionin 7MM 1>4.3. Total Prevalent  Patient Population of Nontuberculous Mycobacteria infectioninfectionin 7MM – By Countries 1>5.     Epidemiology of Nontuberculous Mycobacteria infectioninfectionby Countries 1>5.1. United States 1>5.1.1.      Assumptions and Rationale 1>5.1.2.      Prevalent/Incident Cases of the Nontuberculous mycobacteria 1>5.1.3.      Sub-Type Specific cases of the Nontuberculous Mycobacteria infectioninfection*Indication Specific 1>5.1.4.      Sex- Specific Cases of the Nontuberculous mycobacteria*Indication Specific 1>5.1.5.      Diagnosed Cases of the Nontuberculous mycobacteria 1>5.1.6.      Treatable Cases of the Nontuberculous mycobacteria 1>5.2. EU5 1>5.3. Assumptions and Rationale 1>5.4. Germany 1>5.4.1.      Assumptions and Rationale 1>5.4.2.      Prevalent/Incident Cases of the Nontuberculous mycobacteria 1>5.4.3.      Sub-Type Specific cases of the Nontuberculous mycobacteria* 1>5.4.4.      Sex- Specific Cases of the Nontuberculous mycobacteria* 1>5.4.5.      Diagnosed Cases of the Nontuberculous mycobacteria 1>5.4.6.      Treatable Cases of the Nontuberculous mycobacteria 1>5.5. France 1>5.5.1.      Assumptions and Rationale 1>5.5.2.      Prevalent/Incident Cases of the Nontuberculous mycobacteria 1>5.5.3.      Sub-Type Specific cases of the Nontuberculous mycobacteria* 1>5.5.4.      Sex- Specific Cases of the Nontuberculous mycobacteria* 1>5.5.5.      Diagnosed Cases of the Nontuberculous mycobacteria 1>5.5.6.      Treatable Cases of the Nontuberculous mycobacteria 1>5.6. Italy 1>5.6.1.      Assumptions and Rationale 1>5.6.2.      Prevalent/Incident Cases of the Nontuberculous mycobacteria 1>5.6.3.      Sub-Type Specific cases of the Nontuberculous mycobacteria* 1>5.6.4.      Sex- Specific Cases of the Nontuberculous mycobacteria* 1>5.6.5.      Diagnosed Cases of the Nontuberculous mycobacteria 1>5.6.6.      Treatable Cases of the Nontuberculous mycobacteria 1>5.7. Spain 1>5.7.1.      Assumptions and Rationale 1>5.7.2.      Prevalent/Incident Cases of the Nontuberculous mycobacteria 1>5.7.3.      Sub-Type Specific cases of the Nontuberculous mycobacteria* 1>5.7.4.      Sex- Specific Cases of the Nontuberculous mycobacteria* 1>5.7.5.      Diagnosed Cases of the Nontuberculous mycobacteria 1>5.7.6.      Treatable Cases of the Nontuberculous mycobacteria 1>5.8. United Kingdom 1>5.8.1.      Assumptions and Rationale 1>5.8.2.      Prevalent/Incident Cases of the Nontuberculous mycobacteria 1>5.8.3.      Sub-Type Specific cases of the Nontuberculous mycobacteria* 1>5.8.4.      Sex- Specific Cases of the Nontuberculous mycobacteria* 1>5.8.5.      Diagnosed Cases of the Nontuberculous mycobacteria 1>5.8.6.      Treatable Cases of the Nontuberculous mycobacteria 1>5.9. Japan 1>5.9.1.      Assumptions and Rationale 1>5.9.2.      Prevalent/Incident Cases of the Nontuberculous mycobacteria 1>5.9.3.      Sub-Type Specific cases of the Nontuberculous mycobacteria* 1>5.9.4.      Sex- Specific Cases of the Nontuberculous mycobacteria* 1>5.9.5.      Diagnosed Cases of the Nontuberculous mycobacteria 1>5.9.6.      Treatable Cases of the Nontuberculous mycobacteria 1>6.     Current Treatment & Medical practices 1>6.1. Treatment Algorithm 1>6.2. Treatment Guidelines 1>7.     Unmet Needs of the Nontuberculous mycobacteria 1>8.     Marketed Therapies 1>8.1. Drug A: Company 1 1>8.1.1.      Drug Description 1>8.1.2.      Mechanism of Action 1>8.1.3.      Regulatory Milestones 1>8.1.4.      Advantages & Disadvantages 1>8.1.5.      Product Profile 1>8.2. Drug B: Company 2 1>8.2.1.      Drug Description 1>8.2.2.      Mechanism of Action 1>8.2.3.      Regulatory Milestones 1>8.2.4.      Advantages & Disadvantages 1>8.2.5.      Product Profile 1>9.     Pipeline Therapies – At a glance 1>10.   Key Cross Competition 1>11.   Emerging Therapies for Nontuberculous mycobacteria 1>11.1.       Drug C: Company 3 1>11.1.1.    Drug Description 1>11.1.2.    Clinical Trials Details 1>11.1.3.    Safety and Efficacy Profile 1>11.1.4.    Advantages & Disadvantages  1>11.1.5.    Pipeline Development Activities 1>11.1.6.    Product Profile 1>11.2.       Drug D: Company 4 1>11.2.1.    Drug Description 1>11.2.2.    Clinical Trials Details 1>11.2.3.    Safety and Efficacy Profile 1>11.2.4.    Advantages & Disadvantages  1>11.2.5.    Pipeline Development Activities 1>11.2.6.    Product Profile 1>12.   Nontuberculous mycobacteria: 7MM Market Analysis 1>12.1.       7MM Market Size of Nontuberculous mycobacteria 1>12.2.       7MM Percentage Share of drugs marketed for Nontuberculous mycobacteria 1>12.3.       7MM Market Sales of Nontuberculous Mycobacteria infectioninfectionby Products 1>13.   Nontuberculous mycobacteria: Country-Wise Market Analysis 1>13.1.       United States 1>13.1.1.    Market Size of Nontuberculous Mycobacteria infectioninfectionin United States 1>13.1.2.    Percentage Share of drugs marketed for Nontuberculous Mycobacteria infectioninfectionin United States 1>13.1.3.    Market Sales of Nontuberculous Mycobacteria infectioninfectionby Products in United States 1>13.1.4.    Analysis of Upcoming Therapies and their Impact on the Market 1>13.2.       EU-5 1>13.2.1.    Germany 1>13.2.1.1. Market Size of Nontuberculous Mycobacteria infectioninfectionin Germany 1>13.2.1.2. Percentage Share of drugs marketed for Nontuberculous Mycobacteria infectioninfectionin Germany 1>13.2.1.3. Market Sales of Nontuberculous Mycobacteria infectioninfectionby Products in Germany 1>13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 1>13.2.2.    France 1>13.2.2.1. Market Size of Nontuberculous Mycobacteria infectioninfectionin France 1>13.2.2.2. Percentage Share of drugs marketed for Nontuberculous Mycobacteria infectioninfectionin France 1>13.2.2.3. Market Sales of Nontuberculous Mycobacteria infectioninfectionby Products in France 1>13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 1>13.2.3.    Italy 1>13.2.3.1. Market Size of Nontuberculous Mycobacteria infectioninfectionin Italy 1>13.2.3.2. Percentage Share of drugs marketed for Nontuberculous Mycobacteria infectioninfectionin Italy 1>13.2.3.3. Market Sales of Nontuberculous Mycobacteria infectioninfectionby Products in Italy 1>13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 1>13.2.4.    Spain 1>13.2.4.1. Market Size of Nontuberculous Mycobacteria infectioninfectionin Spain 1>13.2.4.2. Percentage Share of drugs marketed for Nontuberculous Mycobacteria infectioninfectionin Spain 1>13.2.4.3. Market Sales of Nontuberculous Mycobacteria infectioninfectionby Products in Spain 1>13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 1>13.2.5.    United Kingdom 1>13.2.5.1. Market Size of Nontuberculous Mycobacteria infectioninfectionin United Kingdom 1>13.2.5.2. Percentage Share of drugs marketed for Nontuberculous Mycobacteria infectioninfectionin United Kingdom 1>13.2.5.3. Market Sales of Nontuberculous Mycobacteria infectioninfectionby Products in United Kingdom 1>13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 1>13.3.       Japan 1>13.3.1.    Market Size of Nontuberculous Mycobacteria infectioninfectionin Japan 1>13.3.2.    Percentage Share of drugs marketed for Nontuberculous Mycobacteria infectioninfectionin Japan 1>13.3.3.    Market Sales of Nontuberculous Mycobacteria infectioninfectionby Products in Japan 1>13.3.4.    Analysis of Upcoming Therapies and their Impact on the Market 1>14.   Market Drivers 1>15.   Market Barriers 1>16.   Appendix 1>17.   Report Methodology 1>17.1.       Sources 1>18.   DelveInsight Capabilities 1>19.   Disclaimer 1>20.   About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 22: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 27: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 32: Treatable Cases of the Nontuberculous Mycobacteria Infectionin UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 37: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 42:7MM- Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 45: United States-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 48: Germany-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 51: France-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 54: Italy-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 57: Spain-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 60:UK-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nontuberculous Mycobacteria Infectionin USD MM (2017-2028)

Table 63: Japan-Market Share Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nontuberculous Mycobacteria Infectionby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 7: Treatable Cases of the Nontuberculous Mycobacteria Infection in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 12: Treatable Cases of the Nontuberculous Mycobacteria Infection in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 17: Treatable Cases of the Nontuberculous Mycobacteria Infection in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 22: Treatable Cases of the Nontuberculous Mycobacteria Infection in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 27: Treatable Cases of the Nontuberculous Mycobacteria Infection in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 32: Treatable Cases of the Nontuberculous Mycobacteria Infection in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 37: Treatable Cases of the Nontuberculous Mycobacteria Infection in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 42:7MM- Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 45: United States-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 48: Germany-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 51: France-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 54: Italy-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 57: Spain-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 60:UK-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nontuberculous Mycobacteria Infection in USD MM (2017-2028)

Figure 63: Japan-Market Share Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nontuberculous Mycobacteria Infection by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM

Table 2: Total Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 5: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 6: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 7: Treatable Cases of the Nontuberculous Mycobacteria Infectionin United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 11: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 12: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 14: Sub-Type Specific cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 15: Sex- Specific Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 16: Diagnosed Cases of the Nontuberculous Mycobacteria Infectionin France (2017-2028)

Table 17: Treatable Cases of the Nontuberculous Mycobacteria Infectionin Franc